Matthew L. Posard
3 stock trades in the last 12 months, shares they bought or sold themselves (not grants or options).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Every trade Matthew L. Posard reported
| Stock | Trade | Amount | Traded |
|---|---|---|---|
| Sell(10b5-1 plan) | $482K | Nov 18SEC filing | |
| Sell(10b5-1 plan) | $568K | Oct 1SEC filing | |
| Sell(10b5-1 plan) | $2M | Sep 16SEC filing |
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Matthew L. Posard's companies
| Stock | Trades | Quality Score |
|---|---|---|
| 3 |
Alerts for Matthew L. Posard
Use this page
How to cite
Breakaway, Matthew L. Posard: Director at Halozyme Therapeutics (HALO), Nov 18, 2026, getbreakaway.com/insiders/matthew-l-posard
Journalists: email support@getbreakaway.com for the data behind this page.